Fig. 7.

ENPP2 regulated AMPK signaling pathway and interacted with LPL. A Protein expression of p-AMPK, AMPK, SREBP1, and FAS in patient with primary CLL. B Protein expression of p-AMPK, AMPK, SREBP1, and FAS with PF-8380 treatment. C MEC-1, patients with CLL cells were treated with 32 μM PF8380 for 24 h and the cell supernatant LPA levels were measured by ELISA. D LPL was markedly upregulated in CLL public database. Analyses were on the basis of GSE31048. E Patients with CLL with unmutated IGHV presented high LPL expression (GSE69034). F Kaplan–Meier survival curves of patients with CLL from GSE22762 with stratified LPL expression. G, H Correlation between ENPP2 and LPL mRNA expression in patients with CLL from GSE50006 and GSE31048. I qRT-PCR was performed to detect LPL mRNA content in ENPP2 knockdown and overexpression cells. J Western Blot assays for the amount of LPL protein in ENPP2 knockdown and overexpression cells. K Co-immunoprecipitation demonstrated that ENPP2 and LPL could be co-precipitated. Data are shown as mean ± SD of at least three independent experiments, n = 3. *p < 0.05, **p < 0.01, ***p < 0.001